What is Leiomyosarcoma of the Thyroid?

Thyroid leiomyosarcoma is a rare and highly aggressive soft-tissue sarcoma that arises from smooth muscle cells of blood vessels. It most often presents as a rapidly enlarging neck mass while thyroid function remains normal. Due to its low incidence and aggressive clinical course, the prognosis is generally poor. 

Sarcomas represent an exceptionally rare subset of thyroid malignancies. Primary leiomyosarcoma of the thyroid gland is particularly uncommon, accounting for only 0.014% of 28,630 thyroid tumours in one series. The World Health Organisation (WHO) classifies thyroid leiomyosarcoma as a smooth muscle tumour of the thyroid gland. Preoperative diagnosis of thyroid leiomyosarcoma is challenging, as it is difficult to distinguish from anaplastic thyroid carcinoma. Diagnosis relies on the identification of smooth muscle actin (SMA) via immunohistochemical staining. Radical surgical treatment is the standard primary treatment for thyroid leiomyosarcoma. The long-term prognosis remains poor, with approximately 50% of patients dying within a short period after diagnosis. Thyroid leiomyosarcoma remains a fatal tumour, highlighting the need for innovative and more effective therapeutic strategies to improve patient management and outcomes.

Symptoms & Presentation:

• Rapidly growing mass: A fast-enlarging, painless lump in the neck is a common initial presentation.

• Compression: Tumour expansion may compress adjacent anatomical structures, resulting in hoarseness, dysphagia, or dyspnea.

• Airway Compression: Involvement of the trachea may result in shortness of breath (dyspnea) or wheezing.

• Voice Changes: Compression of the laryngeal nerves often causes hoarseness or a reduced vocal pitch.

• Swallowing Difficulties: Compression of the oesophagus may cause painful or difficult swallowing (dysphagia)

• Systemic Symptoms: Unintentional weight loss, fatigue, and occasionally a persistent cough may develop as the disease advances. progresses

• Normal thyroid function: In contrast to most thyroid cancers, laboratory evaluation typically reveals normal thyroid hormone (TSH) levels.

Diagnosis: 

The diagnosis of thyroid leiomyosarcoma typically requires a combination of imaging modalities (such as ultrasound or CT), fine-needle aspiration (FNA) biopsy, and immunohistochemistry to accurately distinguish it from other thyroid malignancies. The standard diagnostic pathway consists of the following:

• Imaging: Ultrasound is typically the initial modality used to visualise the thyroid gland and identify suspicious nodules. This is often followed by CT or MRI to assess tumour size, local tissue invasion, and potential metastatic spread.

• Biopsy and Cytology: Fine needle aspiration is performed to obtain tissue samples for microscopic evaluation.

• Immunohistochemistry (IHC): Leiomyosarcomas typically present as spindle cells under microscopic examination, which may resemble anaplastic thyroid carcinoma. IHC staining is essential to confirm smooth muscle origin. A definitive diagnosis is supported by positive staining for smooth muscle actin (SMA), desmin, and vimentin, and negative staining for epithelial or thyroid-specific markers such as thyroglobulin and cytokeratin.

Treatment: 

The primary treatment is radical surgery, typically a total thyroidectomy with neck dissection. Because these tumours are generally resistant to standard treatments, adjuvant therapies such as radiation or chemotherapy are sometimes used but yield limited benefit. 

Because this is a highly complex diagnosis, treatment must be individualised and managed by a multidisciplinary team (MDT) composed of head and neck surgeons, oncologists, and pathologists. 

Standard management strategies include the following:

1. Surgical Resection.

• Total Thyroidectomy: Complete surgical removal of the thyroid gland serves as the cornerstone of treatment, enabling both definitive diagnosis and excision of the primary tumour. Lymph

• Node Dissection: When regional lymph nodes are involved or clinically enlarged, a lymph node dissection is typically performed in conjunction with thyroidectomy.

2. Adjuvant Therapy.

• Radiation Therapy: Post-operative loco-regional radiotherapy may be administered to reduce the risk of local recurrence.Systemic

• Chemotherapy: While not universally effective, chemotherapy (such as doxorubicin, ifosfamide, or a gemcitabine/docetaxel combination) may be utilised, especially if the disease has metastasised or is advanced.

3. Diagnosis and Immunohistochemistry. 

Accurate diagnosis depends on immunohistochemistry to differentiate this tumour from other aggressive thyroid malignancies, such as anaplastic thyroid carcinoma. Tumour tissue typically shows positivity for smooth muscle markers, including SMA (smooth muscle actin), desmin, and caldesmon.

4. Palliative and Supportive Care

. Due to the aggressive nature and unfavourable prognosis of the disease, supportive care and symptom management are essential components of the patient care plan.

Given the rarity of these tumours, treatment necessitates a specialised multidisciplinary oncology team to formulate an individualised care plan. Additional information regarding soft tissue sarcomas and their treatments is available through the National Cancer Institute.